# Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

Study · id `cardio:ct-nct01912534` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01912534](<https://clinicaltrials.gov/study/NCT01912534>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01912534

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

## Technical summary

Registry record NCT01912534. Randomized; triple masking; primary purpose treatment. Start 2014-03 (actual); primary completion 2019-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 211 participants (enrolled count; ClinicalTrials.gov record NCT01912534, source copy `cardio:ctgov-nct01912534-2021-01-11`, retrieved 2026-10-31)
- Started: 2014-03 (actual) (ClinicalTrials.gov record NCT01912534, source copy `cardio:ctgov-nct01912534-2021-01-11`, retrieved 2026-10-31)
- Primary completion: 2019-07 (actual) (ClinicalTrials.gov record NCT01912534, source copy `cardio:ctgov-nct01912534-2021-01-11`, retrieved 2026-10-31)
- Completion: 2019-07 (actual) (ClinicalTrials.gov record NCT01912534, source copy `cardio:ctgov-nct01912534-2021-01-11`, retrieved 2026-10-31)
- Countries: United States; Canada (ClinicalTrials.gov record NCT01912534, source copy `cardio:ctgov-nct01912534-2021-01-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01912534-2021-01-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
- Acronym: VANISH
- Condition: Hypertrophic Cardiomyopathy
- Intervention (Drug): Valsartan
- Intervention (Drug): Placebo
- Lead sponsor: Carelon Research
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry intervention is a member of this class by a sourced record link: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- Registry lists this organization as the lead sponsor: Carelon Research (`cardio:org-carelon-research`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial (`cardio:pubmed-34556856`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial (`cardio:pubmed-37672268`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial (`cardio:pubmed-39087355`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy (`cardio:pubmed-40042824`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial (`cardio:pubmed-40340372`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Body Mass Index, Valsartan, and Myocardial Remodeling in Early-Stage Hypertrophic Cardiomyopathy: A Secondary Analysis of the Randomized VANISH Trial (`cardio:pubmed-42858009`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fd59c085a8cb71dc11ee44c2913e07af32e0e1e015efc1b99ae04463160b0b1d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
